Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Atricure ( (ATRC) ) has shared an update.
AtriCure reported preliminary financial results for the fourth quarter and full year 2024, with anticipated revenue growth of approximately 17% compared to the previous year. The company expects continued momentum into 2025, with projected revenues of $517 million to $527 million and positive adjusted EBITDA of $40 million to $44 million, driven by strong performance in key product lines and market expansion efforts.
More about Atricure
AtriCure, Inc. is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage management, and post-operative pain management. Its technologies are widely used by electrophysiologists, cardiothoracic, and thoracic surgeons worldwide. Notably, AtriCure’s Isolator Synergy Ablation System is the first FDA-approved device for persistent Afib treatment, and its AtriClip products are the top-selling devices for LAA management globally.
YTD Price Performance: 3.32%
Average Trading Volume: 512,378
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.53B
For an in-depth examination of ATRC stock, go to TipRanks’ Stock Analysis page.
